It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
According to a note out of Morgans, its analysts have retained their buy rating on this appliance manufacturer's shares with an improved price target of $40.65. This follows the release of a better than feared half-year result from Breville this week. It notes that its double-digit sales growth was largely offset by US tariff pressures, leading to a flat net profit outcome. Nevertheless, Morgans continues to be impressed by Breville's strong operational execution, green shoots in food preparation, and powerful medium-term tailwinds. The latter includes geographic expansion and at-home coffee tailwinds. The Breville share price is trading at $32.53 on Friday.
Northern Star Resources Ltd (ASX: NST)
A note out of Citi reveals that its analysts have upgraded this gold miner's shares to a buy rating with an improved price target of $33.40. The broker made the move in response to the company's half-year results this week. It was pleased with the results and management's reiteration of guidance for FY 2026. And while it sees short-term downside risks, the broker feels its valuation is compelling based on the current gold price and its price to net asset value. The Northern Star share price is fetching $28.29 at the time of writing.
Pro Medicus Ltd (ASX: PME)
Analysts at Bell Potter have retained their buy rating on this health imaging technology company's shares with a reduced price target of $240.00. This follows the release of Pro Medicus' half-year results, which were a touch short of expectations. Bell Potter notes that although it delivered a record result with strong revenue and profit growth, its revenue was still a 5% miss. And as it was priced to perfection, it wasn't surprised to see its shares tumble. Outside this, the broker highlights that management spoke about how it doesn't believe AI will disrupt its business. The broker agrees with this and believes that it is well-placed to benefit from increasing demand for radiology services. This is especially the case given how its systems remain a driver of efficiency in radiology. Overall, it believes that following this downgrade and the re-rating now applied to software providers, it is an attractive entry point for investors. The Pro Medicus share price is trading at $120.49 today.
